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The 2015/16 influenza season was the third season 
of the introduction of an intra-nasally administered 
live attenuated influenza vaccine (LAIV) for children 
in England. All children aged 2–6 years were offered 
LAIV, and in addition, a series of geographically dis-
crete areas piloted vaccinating school-age children 
7–11 years old. Influenza A(H1N1)pdm09 was the domi-
nant circulating strain during 2015/16 followed by 
influenza B. We measured influenza vaccine uptake 
and the overall and indirect effect of vaccinating chil-
dren of primary school -age, by comparing cumulative 
disease incidence in targeted and non-targeted age 
groups in vaccine pilot and non-pilot areas in England. 
Uptake of 57.9% (range: 43.6–72.0) was achieved in 
the five pilot areas for children aged 5–11 years. In 
pilot areas, cumulative emergency department res-
piratory attendances, influenza-confirmed hospi-
talisations and intensive care unit admissions were 
consistently lower, albeit mostly non-significantly, in 
targeted and non-targeted age groups compared with 
non-pilot areas. Effect sizes were less for adults and 
more severe endpoints. Vaccination of healthy primary 
school-age children with LAIV at moderately high lev-
els continues to be associated with population-level 
reductions in influenza-related respiratory illness. 
Further work to evaluate the population-level impact 
of the programme is required.
Background
During the 2015/16 influenza season, England and the 
rest of the United Kingdom (UK) was in the third season 
of a new childhood influenza vaccination programme 
targeting healthy children with a recently licensed 
intra-nasally administered live attenuated influenza 
vaccine (LAIV). The programme ultimately aims to offer 
annual influenza vaccination to all children 2–16 years 
of age to both directly protect them, and, by reducing 
their rate of infection, indirectly protect others in the 
community – particularly those who may be at higher 
risk of severe disease following influenza [1]. In this 
third season, the LAIV programme was extended from 
offering the vaccine to all healthy children 2–4 years 
of age to all children in school years 1 and 2, i.e. chil-
dren 5 and 6 years of age across England. In addition, 
as in the 2 previous years, a series of five geographi-
cally discrete pilots were undertaken in England. In 
these pilots, the remaining healthy children of primary 
school age in school years 3 to 6 i.e. children aged 7–11 
years, were also offered LAIV, with uptake exceeding 
50% [2,3].
The key evidence supporting the introduction of the 
UK childhood LAIV programme was mathematical 
transmission modelling that predicted and quantified 
the future impact, combined with an economic evalu-
ation to determine the most cost-effective approach 
[4]. Since then, recently published evidence from the 
UK has shown that LAIV has been effective in children 
over these first three seasons [5]. Furthermore, the 
first 2 years of the LAIV programme provided encourag-
ing evidence, albeit often not statistically significant, 
showing that vaccinating children of primary school 
age was associated with reductions in incidence for a 
range of influenza disease indicators in both targeted 
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and non-targeted age groups when comparing pilot 
and non-pilot areas in England [6,7]. To date, only lim-
ited data has been published internationally of the 
observed impact of such programmes [8-10].
The 2015/16 influenza season in the UK started late, 
with peak activity in week 11/12, and was initially 
dominated by circulation of influenza A(H1N1)pdm09. 
Disease impact was particularly seen in younger 
adults, resulting in large numbers of hospitalisations 
and intensive care unit (ICU) admissions in these age 
groups. However, neither level reached those observed 
in the last significant A(H1N1)pdm09 season of 2010/11. 
The latter part of this recent season saw influenza B 
circulation, particularly of the B/Victoria lineage [3]. 
End-of-season UK vaccine effectiveness (VE) analyses 
Figure 1
Cumulative uptake of live attenuated influenza vaccine in primacy school-age childrena in pilot areas, England, week 40 
2015–week 20 2016
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for the 2015/16 season reported that overall LAIV effec-
tiveness in children 2 to 17 years of age in the UK was 
57.6% (95% CI: 25.1–76.0) [5]. However, data emerging 
from the United States (US) found little evidence of the 
effectiveness of LAIV in protecting children during the 
2015/16 season, resulting in the Advisory Committee 
on Immunization Practices temporarily suspending 
the recommendation to use LAIV in the US [11]. The 
reason for the discrepancy in VE between the US and 
UK remains under investigation: a description of the 
potential population impact of vaccinating children 
with LAIV for the 2015/16 season will help to guide 
the future paediatric vaccine strategy. The aim of this 
paper is to describe the uptake of influenza vaccine in 
children, to evaluate the indirect and total impact of 
vaccinating children of primary school age in England 
in the 2015/16 season against a range of influenza-
related indicators, and to compare these indicators in 
the pre-and post-paediatric influenza vaccine era.
Methods
The majority of the England pilot areas that started 
vaccinating primary school-age children with LAIV in 
2013/14 continued with the programme in 2015/16 
[6,7]. All pilot areas delivered the programme through 
a school-based approach.
Measuring vaccine uptake
The target population for vaccination in pilot areas was 
defined as children of primary school age, i.e. children 
5–10, but not 11 years or older (as defined by the child 
age on 1 September 2015) born between 1 September 
2004 and 31 August 2010, resident in five areas in 
England: Greater Manchester (Bury); Leicestershire 
and Lincolnshire (Leicester City, Leicestershire, and 
Rutland); London (Havering); Essex (Essex, Southend-
On-Sea, Thurrock); and Northumberland & Tyne and 
Wear (Gateshead, South Tyneside, Sunderland).
Commissioned data providers who were responsible for 
delivery of the childhood influenza programme in pilot 
areas collected and reported vaccination data to Public 
Health England (PHE) using ImmForm, a web-based 
reporting system [12]. Vaccine uptake was calculated 
from the number of children in the target population 
who received at least one dose of influenza vaccine 
in the period from 1 September 2015 until 31 January 
2016. LAIV was offered to healthy children and at-risk 
children in whom vaccine was not contraindicated. 
For those at-risk children in whom LAIV was contrain-
dicated, quadrivalent inactivated vaccine was offered 
instead.
Figure 2
Cumulative primary care ILI surveillance indicators in primary school pilot and non-pilot areas (A) consultation rate and 
(B) positivity ratea from the RCGP ILI surveillance network with integrated microbiological surveillance, England, week 40 
2015–week 20 2016
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Measuring school-age vaccine programme 
impact
The period of the impact study ran from week 40 2015 
until week 20 2016, which is when influenza transmis-
sion ceased for the 2015/16 season [3].
The overall impact of the LAIV primary school-age 
programme for a range of virological and clinical end-
points in primary and secondary care as well as excess 
mortality was defined as Cumulative disease incidence 
in non-pilot areas – Cumulative disease incidence in 
primary school-age pilot areas.
As in previous studies, this was examined across four 
age groups to measure the impact of vaccination in tar-
geted and non-targeted age groups. First, the impact 
in children of primary school age, i.e. 5–10 years of 
age (targeted age group). Second, the indirect impact 
in children less than 5 years of age, individuals 11–16 
years of age and individuals 17 years of age (non-tar-
geted age-groups) [7].
The cumulative, age-group-specific influenza indica-
tors in pilot and non-pilot areas before vaccine pro-
gramme introduction, i.e. 2011/12 and 2012/13, and 
after vaccine programme introduction, i.e. 2013/14, 
2014/15 and 2015/16, in England were also compared.
Data sources
A range of sentinel surveillance systems were used to 
measure the impact of vaccinating children of primary 
school age. Additional sentinel general practitioners 
Figure 3
Cumulative secondary care surveillance indicators in primary school pilot and non-pilot areas from four surveillance 
networks, England, week 40 2015–week 20 2016
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Figure 4
Cumulative weekly all-cause mortality in primary school pilot and non-pilot areas by influenza season, England, week 40 
2011–20 2016
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Figure 5
Cumulative weekly respiratory excess mortality in primary school pilot and non-pilot areas by influenza season, England, 
week 40 2011–week 20 2016
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Figure 6
Cumulative, age-specific influenza indicators in pilot and non-pilot areas, by notification systems, England, week 40 2011–
week 20 2016a
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Figure 7
Cumulative, age-specific influenza indicators in pilot and non-pilot areas, by notification system, England, week 40 2011–
week 20 2016a
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(GPs), emergency departments (ED) and hospitals were 
recruited in the pilot areas since the first season of the 
introduction of the LAIV programme in 2013/14.
Primary care
Primary care surveillance was undertaken through the 
Royal College of General Practitioners (RCGP) Research 
and Surveillance Centre (RSC) Weekly Returns Service 
sentinel GP network. This system reported weekly influ-
enza-like illness (ILI) consultations in primary care. One 
hundred-forty-six RCGP practices participated in non-
pilot areas and 10 practices in pilot areas. Seventy of 
these RCGP practices together with 22 practices from 
a further sentinel network, the Specialist Microbiology 
Network (SMN), collected respiratory swabs from a 
sample of patients consulting with ILI, regardless of 
vaccination status.
Secondary care
The UK Severe Influenza Surveillance System (USISS) 
includes two schemes. First, USISS sentinel, a volun-
tary network of 27 National Health Service (NHS) hospi-
tal trusts across England (22 in non-pilot areas and five 
in pilot areas in 2015/16), reported the weekly number 
of laboratory-confirmed influenza hospital admis-
sions [13]. Estimated hospital catchment populations 
were used to calculate weekly laboratory confirmed 
hospitalisation rates per 100,000 population [14] as 
previously documented by pilot area and age group. 
Second, USISS mandatory, which involves all ICU and 
high dependency units (HDU) in England (136 units 
in non-pilot areas and 11 in pilot areas in 2015/16), 
reported the number of laboratory-confirmed influenza 
admissions each week. Admission rates by age group 
and pilot area were calculated as for the USISS sentinel 
scheme [13].
The Emergency Department Syndromic Surveillance 
System (EDSSS), is a sentinel network of emergency 
departments (ED) that monitors weekly ED attendances 
[15] and the proportion of all weekly attendances coded 
as respiratory in pilot (one ED) and non-pilot areas (24 
EDs) by age group.
The Respiratory DataMart scheme (RDMS), collates 
and reports all influenza reverse-transcription-PCR 
(RT-PCR) respiratory swab results in a network of PHE 
and NHS laboratories in England; the majority of sam-
ples (> 90%) came from secondary care [16] and were 
used to compare the influenza cumulative positivity 
over the study period. Postcode of residence was used 
to classify whether a sample was taken from a patient 
residing in a pilot or non-pilot area. Swab positivity 
was compared by age group and pilot area.
Excess mortality
Routine death registration data from the Office for 
National Statistics was used to calculate excess mor-
tality each week using the European Monitoring of 
Excess Mortality for Public Health Action (EuroMOMO) 
standard algorithm [17]. The observed number of 
Figure 8
Cumulative, age-specific influenza indicators in pilot and 
non-pilot areas, England, week 40 2011–week 20 2016a
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previously published work [7]. The primary pilot areas in the 
2014/15 season were applied to calculate rates at each reporting 
level, excluded secondary pilots areas.
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weekly death occurrences, corrected for reporting 
delay, was compared with the expected number of 
deaths, based upon historical patterns, to determine 
if there was statistically significant excess mortality. 
Excess mortality was estimated in both non-pilot and 
pilot areas based upon place of usual residence. The 
algorithm was applied to both all-cause mortality and 
death registrations where respiratory, ICD-10 ‘J’ code, 
was the primary cause of death [18].
Statistical methods
Cumulative disease incidence rates per 100,000 pop-
ulation were calculated for the RCGP, USISS sentinel 
and USISS mandatory schemes, by summing the num-
ber of weekly disease episodes (from week 40 2015 to 
week 20 2016) over the average weekly population at 
risk based on the GP registered or hospital catchment 
population respectively. Calculations were undertaken 
overall and by age group for both pilot and non-pilot 
areas. Exact Poisson confidence intervals (CI) were 
calculated.
Cumulative influenza swab positivity for the GP swab-
bing (from RCGP and SMN) and RDMS were calculated 
by summing the number of positive samples over the 
total number of samples tested in the study period. 
Cumulative proportion of ED attendances coded as 
respiratory were calculated by summing the total num-
ber of respiratory coded ED attendances over the total 
number of ED attendances with a diagnosis during the 
study period. Calculations were undertaken overall and 
by age group and pilot area. Exact CIs were calculated.
To measure the impact of primary school vaccination, 
the non-pilot areas were set as reference and odds 
ratios (ORs) and 95% CIs were calculated by age group 
and surveillance system. To adjust for clustering at the 
reporting unit level, e.g. by GP, hospital, laboratory, 
data were converted to binomial individual level across 
schemes and random effects logistic regression was 
undertaken.
Cumulative excess mortality rates by pilot and non-
pilot area were calculated by summing the difference 
between observed and expected weekly deaths over 
the study period, and using the resident population in 
pilot and non-pilot areas.
Table 1
Adjusted impact of vaccinating primary school-age children on selected primary care influenza surveillance indicators, 
England, influenza season, 2015/16a
Age group Measure
RCGP ILI consultation rate (per 100,000 
population) Sentinel influenza swab positivity (%)
Non-pilot area Pilot areab Non-pilot area Pilot areab
Primary school 5–10 years
Rate 234.7 75.8 37.3 33.3
(n/N) (225/95,857) (5/6,593) (63/169) (5/15)
Risk difference
Ref
-158.9
Ref
-4.0
OR (95% CI) 0.31 (0.08 to 1.15) 0.96 (0.23 to 4.03)
p value 0.080 0.961
Secondary school 11–16 years
Rate 283.0 81.1 40.9 27.3
(n/N) (249/87,979) (5/6,164) (63/154) (3/11)
Risk difference
Ref
-201.9
Ref
-13.6
OR (95% CI) 0.28 (0.08 to 0.91) 0.54 (0.14 to 2.12)
p value 0.034 0.379
Other age groups
  < 5 years
Rate 248 39.5 41.1 35.3
(n/N) (197/79,449) (2/5,057) (99/241) (6/17)
Risk difference
Ref
-208.5
Ref
-5.8
OR (95% CI) 0.14 (0.02 to 1.18) 0.97 (0.16 to 5.71)
p value 0.071 0.971
  ≥ 17 years
Rate 400.3 167.5 28.1 16.5
(n/N) (4,529/1,131,418) (122/72,842) (648/2,308) (39/237)
Risk difference
Ref
-232.8
Ref
-11.6
OR (95% CI) 0.37 (0.16 to 0.90) 0.52 (0.32 to 0.84)
p value 0.029 0.008
CI: confidence interval; ILI: influenza-like illness; OR: odds ratio; RCGP: Royal College of General Practitioners.
a Week 40 2015 to week 20 2016.
b Includes primary school pilot areas.
p values < 0.05 are in bold.
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Comparison for the post-introduction (2013/14, 
2014/15, 2015/16) and pre-introduction periods 
(2011/12, 2012/13) was undertaken for the cumulative, 
age-specific influenza incidence in pilot and non-pilot 
areas. The pre-vaccination pilot areas were the same 
as those defined for the 2015/16 season.
Laboratory methods
Influenza laboratory confirmation of samples from pri-
mary and secondary care was undertaken on respira-
tory samples using comparable real-time PCR methods 
able to detect circulating influenza A and influenza B 
viruses [19,20]. Samples from the RCGP sentinel GP 
scheme were sent to the PHE Reference Virus Unit in 
Colindale; samples from the SMN sentinel GP scheme 
and secondary care were sent to one of the network of 
specialist PHE microbiology laboratories (SMN scheme) 
or NHS laboratories elsewhere in England (secondary 
care).
Results
Vaccine uptake
The total target population for the primary school 
pilots was estimated to be 279,933 primary school-age 
children.
An estimated 162,013 primary school-age children in 
pilot areas received at least one dose of influenza vac-
cine resulting in an overall uptake of 57.9%. This ranged 
from 43.6% to 72.0% at the pilot-site level (Figure 1). 
Uptake by school year group ranged from 62.6% in year 
1 (children 5 to 6 years of age), 60.1% in year 2 (chil-
dren 6 to 7 years of age), 57.2% in year 3 (children 7 to 
8 years of age), 56.2% in year 4 (children 8 to 9 years of 
age), 56.0% in year 5 (children 9 to 10 years of age), to 
54.7% in year 6 (children 10 to 11 years of age).
 
Influenza vaccine uptake achieved in children 2–4 
years of age in primary school pilot areas was 34.0% 
in 584 GP practices compared with 34.4% in 7,029 GP 
practices in non-pilot areas elsewhere in England. For 
children in school years 1 and 2, i.e. children 5 and 6 
years of age, uptake was 61.4% (58,920/96,036) in 
pilot areas compared with 53% (658,008/1,240,567) in 
non-pilot areas elsewhere in England.
School age vaccine programme impact
Patterns of activity
The cumulative ILI consultation rate and sentinel GP 
swab positivity in primary care, ED respiratory attend-
ances, RDMS influenza positivity and ICU/HDU rates 
in secondary care from week 40 2015 to week 20 2016 
were consistently lower in primary school-age pilot 
areas compared with non-pilot areas in both the tar-
geted and non-targeted age groups (Figures 2  and  3). 
These differences were less marked for the sentinel 
GP swab positivity, RDMS indicators and laboratory-
confirmed ICU admissions particularly in the older, 
non-targeted age group of individuals 17 years of age 
and over.
 
All-cause and respiratory excess mortality
All-cause excess mortality was significantly higher in 
pilot areas during both the pre-vaccine (2011/12 and 
2012/13) and post-vaccine period (2013/14, 2014/15 
and 2015/16) (Figure 4). For all-age respiratory deaths, 
there was no significant difference between pilot and 
non-pilot areas during the pre-vaccine period (2011/12 
and 2012/13). However, in the post-vaccine period, 
cumulative excess respiratory deaths were significantly 
lower in both 2013/14 and 2015/16 seasons (Figure 5).
 
Pre-vaccination information for indicators with 
available data
Data were available for RCGP ILI and influenza con-
firmed hospitalisations and ICU admissions. During the 
two seasons before the start of the childhood vaccina-
tion programmes, the cumulative ICU/HDU admission 
and hospitalisation rates for influenza were similar 
between the targeted and non-targeted age groups in 
pilot areas compared to those in non-pilot areas. In 
comparison, GP ILI consultation rates were consistently 
lower during the two seasons prior to the programme 
introduction in the pilot areas compared with non-
pilot areas. For all indicators, there was a divergence 
between pilot and non-pilot areas in both targeted and 
non-targeted age groups with the introduction of the 
childhood influenza vaccine programme in 2013/14 
with a relative reduction for indicators in pilot areas 
compared to non-pilot areas (Figure 6, 7, 8).
Adjusted impact for primary and secondary care 
surveillance indicators
Vaccinating primary school age children resulted in 
significant reductions in cumulative incidence/labora-
tory-confirmed positivity in primary care indicators for 
ILI and swab positivity in adults when comparing pilot 
with non-pilot areas and adjusting for clustering (Table 
1). There were also non-significant reductions for ILI GP 
consultations and swab positivity in both children of 
primary school age and those less than 5 years of age 
(Table 1)
For the secondary care indicators, i.e. for influenza-
confirmed hospitalisations and ICU admissions, ED 
attendances and DataMart positivity, reductions were 
seen in all instances in the targeted age group when 
comparing pilot to non-pilot areas, though this was 
only statistically significant for laboratory-confirmed 
hospitalisations (Table 2). The size of these reductions 
was less and non-significant when examining chil-
dren less than 5 years of age and those of secondary 
school age. There was little evidence of any reduction 
for these indicators when comparing pilot and non-
pilot areas among adults (Table 2).
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Discussion
This study assesses the uptake of LAIV and evalu-
ates the impact of the recently implemented LAIV pro-
gramme for children in England that was targeted at 
primary school-age children in discrete geographical 
pilot areas during the 2015/16 influenza season. We 
found similar levels of uptake during this season, when 
compared with the first two seasons and that vaccinat-
ing children of primary school age was associated with 
reductions in incidence for a range of surveillance indi-
cators in England. This effect was most evident in areas 
where all children of primary school age had been tar-
geted, with the impact most noticeable in targeted age 
groups. The size of the effect was less for more severe 
endpoints such as excess respiratory mortality, and 
for non-targeted age groups e.g. adults and secondary 
school-age children.
The 2015/16 influenza season was characterised by 
significant numbers of hospitalisations and ICU admis-
sions and some fatalities among younger adults, an 
observation consistent with the circulation of influenza 
A(H1N1)pdm09 virus [3]. We observed decreases in 
influenza in primary school-age children (and indirectly 
in children under the age of 5 years, where the burden 
of influenza is recognised to be highest) together with 
smaller indirect reductions in secondary school-age 
children and adults in primary school age pilot areas. 
These indirect reductions seen for primary care con-
sultations, laboratory-confirmed hospitalisations, ICU/
HDU admissions and ED attendances, however, were 
not statistically significant. As seen in the first two 
seasons of the programme, the effect sizes generally 
became smaller as the endpoints were more severe 
[6,7], which is consistent with publications from else-
where [8-10]; in particular, a study by King et al., who 
reported significant reductions in medically attended 
acute respiratory illnesses (MAARI) emergency depart-
ment visits in children and young adults, but less so for 
hospitalisations (particularly in the elderly) associated 
with increases in LAIV uptake in primary school-age 
children [10].
We report good uptake levels in primary school-age 
children in pilot areas. A study by Calder et al. found 
that school–based influenza vaccine programmes 
achieved better equity by ethnicity and deprivation, 
though primary care delivery can also achieve impor-
tant increases in uptake [21]. This reinforces this 
approach as a model of delivery for vaccinating chil-
dren of school age.
A recent systematic review identified some evidence 
that vaccinating children can provide indirect benefits 
particularly against milder endpoints, but highlighted 
that larger scale studies were required against a range 
of endpoints in different settings [22]. Our study starts 
to address that need. The findings in this article are 
also encouraging in the light of observations in the US 
in 2015/16, where observational studies indicated that 
LAIV has had little or no effect among children [11]. This 
is in contrast to findings of moderate VE in other geo-
graphical settings such as the UK, Canada and Finland 
[23]. The reasons for these observations remain under 
investigation, though preliminary work has suggested 
impaired replicability of the A/California-like LAIV 
strain A/Bolivia (H1N1)pdm09 in 2015/16 [24]. This 
strain has since been updated in the vaccine, so it will 
be important to evaluate the direct and indirect popu-
lation impact of this new LAIV vaccine virus.
The reductions we observed occurred in a season in 
which new genetic subgroups in influenza A(H1N1)
pdm09 viruses emerged (6B.1 and 6B.2) and circulated 
as the predominant strains. These factors raised some 
concerns about possible vaccine mismatch, together 
with the end of season LAIV VE findings of 58% (over-
all) and of 42% against A(H1N1)pdm09 in children 
2–17 years of age [5]. Our results suggest that average 
uptake levels of 58% among all primary school-age 
children compared with the rest of the country – where 
only primary school-age children in school years 1 
and 2 were offered vaccine, will result in reduction in 
influenza transmission in the local population. This is 
evidenced by observation of both direct and indirect 
impacts for a range of indicators in primary and (to a 
lesser extent) secondary care in these local areas.
Although there were reductions in a range of clini-
cal endpoints in pilot compared with non-pilot areas 
in young adults, the differences were non-significant 
and became less for more severe indicators and the 
older age groups. The lesser effects observed could be 
related to how children interact with vulnerable groups 
such as the elderly particularly in settings such as care 
homes; other studies have also not been able to deter-
mine a significant difference [10]. Further research is 
planned to look at these differences, as this is where 
much of the health economic benefits of a school-age 
influenza vaccination programme were projected to be 
derived [4].
This study builds upon methodology developed in the 
first two seasons of the recently established childhood 
LAIV programme in order to evaluate its uptake and 
impact. The use of population-level data sources is a 
strength of this study, as we were able to compare our 
findings, in relation to vaccine uptake, with earlier pub-
lished research [6,7] and assess their impact across a 
range of indicators when primary school children were 
targeted. Examination of historical data suggests some 
caution is needed in interpretation, however, as there 
are pre-vaccine era programme differences in regard to 
primary care ILI consultation rates between pilot and 
non-pilot areas. The practices in pilot areas are more 
likely to have been newly recruited, which may explain 
pre-vaccination differences in reporting practice. The 
apparent effect sizes of this particular indicator should 
thus not be overestimated, with the majority of them 
non-significant in the models, which also take into 
account clustering at the reporting unit level. The on-
going roll-out of the national programme to increasing 
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age cohorts of school children (in 2016/17, the pro-
gramme additionally included children aged 3 and 7 
years and in 2017/18 to children aged 8 years) will result 
in less notable differences in vaccine uptake between 
pilot and non-pilot areas; and thus the opportunity 
to undertake such comparative observational studies 
between geographical areas is, therefore, diminishing. 
Finally, the size of the pilot areas is relatively small, so 
results should be interpreted with caution as we had 
limited power to detect significant differences, particu-
larly for more severe endpoints.
The differential roll-out of the LAIV programme across 
the countries of the UK, with Scotland and Northern 
Ireland vaccinating primary school-age children and 
Wales secondary school-age children in 2015/16 has 
shown some early encouraging signs in relation to 
reductions in primary care consultations for those coun-
tries vaccinating primary school-age children [3]. This 
study in England provides further important opportuni-
ties to understand the population level impacts of the 
universal paediatric influenza vaccination programme.
Conclusion
In conclusion, our findings support the on-going roll out 
of the national LAIV programme for children of primary 
school age. Further work will need to be undertaken to 
evaluate the impact of the LAIV programme against a 
range of endpoints, in particular, the more severe ones 
such as those against mortality and to investigate the 
discordance observed between the UK and US paediat-
ric programmes.
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